Radiation Protection and Occupational Exposure on Ga-PSMA-11-Based Cerenkov Luminescence Imaging Procedures in Robot-Assisted Prostatectomy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
PMID:

Abstract

Cerenkov luminescence imaging (CLI) was successfully implemented in the intraoperative context as a form of radioguided cancer surgery, showing promise in the detection of surgical margins during robot-assisted radical prostatectomy. The present study was designed to provide a quantitative description of the occupational radiation exposure of surgery and histopathology personnel from CLI-guided robot-assisted radical prostatectomy after the injection of Ga-PSMA-11 in a single-injection PET/CT CLI protocol. Ten patients with preoperative Ga-PSMA-11 administration and intraoperative CLI were included. Patient dose rate was measured before PET/CT ( = 10) and after PET/CT ( = 5) at a 1-m distance for 4 patient regions (head [A], right side [B], left side [C], and feet [D]). Electronic personal dosimetry (EPD) was used for intraoperative occupational exposure ( = 10). Measurements included the first surgical assistant and scrub nurse at the operating table and the CLI imager/surgeon at the robotic console and encompassed the whole duration of surgery and CLI image acquisition. An estimation of the exposure of histopathology personnel was performed by measuring prostate specimens ( = 8) with a germanium detector. The measured dose rate value before PET/CT was 5.3 ± 0.9 (average ± SD) μSv/h. This value corresponds to a patient-specific dose rate constant for positions B and C of 0.047 μSv/h⋅MBq. The average dose rate value after PET/CT was 1.04 ± 1.00 μSv/h. The patient-specific dose rate constant values corresponding to regions A to D were 0.011, 0.026, 0.024, and 0.003 μSv/h⋅MBq, respectively. EPD readings revealed average personal equivalent doses of 9.0 ± 7.1, 3.3 ± 3.9, and 0.7 ± 0.7 μSv for the first surgical assistant, scrub nurse, and CLI imager/surgeon, respectively. The median germanium detector-measured activity of the prostate specimen was 2.96 kBq (interquartile range, 2.23-7.65 kBq). Single-injection Ga-PSMA-11 PET/CT CLI procedures are associated with a reasonable occupational exposure level, if kept under 110 procedures per year. Excised prostate specimen radionuclide content was below the exemption level for Ga. Dose rate-based calculations provide a robust estimation for EPD measurements.

Authors

  • Pedro Fragoso Costa
    Department of Nuclear Medicine, University Hospital Essen, Essen, Germany; pedro.fragoso-costa@uni-duisburg-essen.de christopher.darr@uk-essen.de.
  • Wolfgang P Fendler
    Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.
  • Ken Herrmann
    Department of Nuclear Medicine, Universitätsklinikum Essen, Essen, Germany.
  • Patrick Sandach
    Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.
  • Hong Grafe
    Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.
  • Maarten R Grootendorst
    Clinical Department, Lightpoint Medical Ltd., Chesham, United Kingdom; and.
  • Lukas Püllen
    German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
  • Claudia Kesch
    British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Ulrich Krafft
    German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
  • Jan P Radtke
    German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
  • Stephan Tschirdewahn
    German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
  • Boris A Hadaschik
    From the Department of Radiology (D.B., P.S., J.P.R., P.K., K.Y., M.F., H.P.S.), Division of Medical Image Computing (S.K., M.G., N.G., K.H.M.H.), Division of Statistics (M.W.), and Department of Medical Physics (T.A.K., F.D.), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany (D.B., H.P.S., K.H.M.H.); and Departments of Urology (J.P.R., B.H., M.H., B.A.H.) and Neuroradiology (P.K.), University of Heidelberg Medical Center, Heidelberg, Germany.
  • Christopher Darr
    German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany; pedro.fragoso-costa@uni-duisburg-essen.de christopher.darr@uk-essen.de.